Skip to main content

Table 4 Validation of parametric survival models for OS

From: Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States

Data source

OS curve

Proportion in OS (%)

Median OS, month

Mean OS, month

6 months

1 year

2 years

3 years

4 years

5 years

10 years

15 years

20 years

25 years

Dependent 1-knot spline normal (base-case analysis)

NIVO

89.9

75.0

53.0

38.5

29.0

22.4

8.3

3.9

2.2

1.3

26.0

45.5

EVE

84.4

66.0

42.6

29.0

20.7

15.4

4.9

2.2

1.1

0.6

19.4

34.8

Independent Weibull curves

NIVO

90.0

76.5

53.9

36.6

24.1

15.6

1.4

0.1

< 0.01

< 0.001

26.3

34.0

EVE

84.3

67.6

43.9

28.0

17.6

11.0

1.0

0.1

< 0.01

< 0.001

20.4

28.3

Dependent log-logistic curve

NIVO

89.7

74.8

53.0

39.0

29.9

23.8

10.6

6.3

4.3

2.9

26.0

50.9

EVE

85.0

65.9

42.3

29.3

21.7

16.9

7.2

4.2

2.8

1.9

19.1

39.5

CheckMate 025

NIVO

89.2

76.0

25.0

EVE

81.2

66.7

19.55

CA209-003

NIVO

82.4

70.6

48.1

41.2

37.8

34.3

22.4a

EVE

  1. The median OS for 1 mg/kg dosing group was 29.3 months; for 10 mg/kg dosing group, the median OS was 18.8 months
  2. EVE, everolimus; NIVO, nivolumab; OS, overall survival
  3. aBoth 1 and 10 mg/kg